References
- Boivin J, Bunting L, Collins JA, et al. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 2007;22:1506–12
- Macaluso M, Wright-Schnapp TJ, Chandra A, et al. A public health focus on infertility prevention, detection, and management. Fertil Steril 2010;93:16.e1–10
- Agarwal A, Mulgund A, Hamada A, et al. A unique view on male infertility around the globe. Reprod Biol Endocrinol 2015;13:37
- Datta J, Palmer MJ, Tanton C, et al. Prevalence of infertility and help seeking among 15 000 women and men. Hum Reprod 2016;31:2108–2118
- Mascarenhas MN, Flaxman SR, Boerma T, et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med 2012;9:e1001356
- Magali M, Magali B. Breton D, et al. Recent demographic developments in France: a decline in fertility, an increase in mortality. Population-F 2016;71(3):395–454
- Mazuy M, Barbieri M, d’Albis H. Recent demographic trends in France: the number of marriages continues to decrease. Population-E 2014;69(3):273–322
- EMA. Ovaleap: EPAR Public Assessment Report. United Kingdom; 2013
- EMA. Gonal-F: Summary of Product Characteristics. United Kingdom; 2010
- EMA. Bemfola: EPAR Public Assessment Report. United Kingdom; 2014
- Haute Autorité de Santé. Avis de la commision de transparence- GONAL-F. 2014. Available at: https://www.has-sante.fr/portail/jcms/c_1773269/fr/gonal-f [Last accessed August 16, 2018]
- Rettenbacher M, Andersen AN, Garcia-Velasco JA, et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. Reprod Biomed Online 2015;30:504–13
- Strowitzki T, Kuczynski W, Mueller A, et al. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol 2016;14:1
- ISPOR. Good Practices for Outcomes Research. USA; 2003. Available at: https://ispor.org/heor-resources/good-practices-for-outcomes-research [Last accessed August 16, 2018]
- ATIH. Présentation | Publication ATIH PMSI MCO. France; 2017. Available at: https://www.atih.sante.fr/mco/presentation [Last accessed August 16, 2018]
- IQVIA. Questionnaire de prise en charge des patientes ayant recours à une aide médicale à la procréation. France; 2017.
- AMELI. Actes à domicile. France; 2017. Available at: https://www.ameli.fr/infirmier/exercice-liberal/facturation-remuneration/tarifs-conventionnels/actes-domicile [Last accessed August 16, 2018]
- AMELI. Le codage des actes biologiques - NABM. France; 2017. Available at: https://www.ameli.fr/medecin/exercice-liberal/facturation-remuneration/nomenclatures-codage/codage-actes-biologiques-nabm [Last accessed August 16, 2018]
- AMELI. CCAM en ligne - CCAM. Available at: https://www.ameli.fr/accueil-de-la-ccam/index.php [Last accessed August 16, 2018]
- ATIH. Tarifs MCO et HAD | Publication ATIH. France; 2017. Available at: https://www.atih.sante.fr/tarifs-mco-et-had [Last accessed August 16, 2018]
- Aitken M. Delivering on the potential of biosimilar medicines: The role of functioning competitive markets introduction. IMS Institute for Health Care Informatics 2016;3–36
- GABI. France to allow biosimilars substitution. Generics and Biosimilars Initiative 2014. Available at: http://gabionline.net/Policies-Legislation/France-to-allow-biosimilars-substitution
- Freiberg M, Schwarz R, Khoury C. Biosimilars: market access and market penetration – a comparison of France and Germany. Value Health 206;19:A442. Available at: https://www.valueinhealthjournal.com/article/S1098-3015(16)31919-2/abstract [Last accessed August 16, 2018]
- Gizzo S, Garcia-Velasco JA, Heiman F, et al. A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility. Int J Womens Health 2016;8:683–9
- Ripellino C, Visentin E, Gizzo S, et al. A cost-effectiveness evaluation comparing biosimilar Bemfola to Gonal-F for the treatment of infertility in an Italian contest. Value Health 2015;18:A735
- Silverio N, Botica F, Batista AR. Cost-effectiveness of recombinant human follicle stimulating hormone biosimilars in Portugal. Value Health 2016;19:A402–A403
- Gizzo S, Ferrando M, Lispi M, et al. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. J Med Econ 2018;1–6 [doi:10.1080/13696998.2018.1511567]
- Gerli S, Bini V, Favilli A, et al. Clinical efficacy and cost-effectiveness of HP-human FSH (Fostimon®) versus rFSH (Gonal-F®) in IVF-ICSI cycles: a meta-analysis. Gynecol Endocrinol 2013;29:520–9
- Al-Inany HG, Abou-Setta AM, Aboulghar MA, et al. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol 2009;25:372–8
- Gholami H, Vicari E, Molis M, et al. Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women aged <37, undergoing ovulation induction with human FSH compared with recombinant FSH: a randomised controlled study. Eur Rev Med Pharmacol Sci 2010;14:97–102
- Sagnella F, Moro F, Lanzone A, et al. A prospective randomized noninferiority study comparing recombinant FSH and highly purified menotropin in intrauterine insemination cycles in couples with unexplained infertility and/or mild-moderate male factor. Fertil Steril 2011;95:689–94
- AMELI. Présentation BdM_IT. France; 2017. Available at: http://www.codage.ext.cnamts.fr/codif/bdm_it/index_presentation.php?p_site=AMELI [Last accessed August 16, 2018]
- Financement. Modalités de FINANCEMENT 2016 des activités d’AMP et de CPDPN. Agence de la biomédecine, France; 2016